Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Intraperitoneal Mesothelin-Targeted CAR T-Cell Therapy in Patients With Mesothelin-Positive Esophagogastric Adenocarcinoma With Peritoneal Carcinomatosis

NCT06623396 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT06623396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06623396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Intraperitoneal Mesothelin-Targeted CAR T-Cell Therapy in Patients With Mesothelin-Positive Esophagogastric Adenocarcinoma With Peritoneal Carcinomatosis
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2024
Completion date
September 30, 2028
Enrollment
18 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, diabetes mellitus, esophageal adenocarcinoma, esophageal adenocarcinomas, esophagogastric adenocarcinoma, mesothelin positive, mesothelin-expressing tumors, peritoneal carcinomatosis